Drug registration a linchpin in Creso Pharma’s penetration of animal health care market
Creso Pharma (ASX: CPH), a leading player in the global development of cannabis and hemp derived therapeutic grade nutraceutical products for humans and animals has, along with its partner Greveling Holding BV, been granted the first and unique European Union registration for two animal health CBD (cannabidiol) based nutraceutical products in a proprietary formulation in the category of animal feed for commercialisation in the global companion animal market.
These CBD nutraceutical products are unique and the first in the world to obtain registration with health authorities compared to unregistered competitor products sold via the internet.
This is a breakthrough development for Creso, particularly given the size and location of its addressable markets. In 2015 the global veterinary health care market was US$25 billion and this is expected to increase to nearly US$40 billion by 2021.
Importantly, Creso is well-positioned to export into European, Middle Eastern gulf region, and Latin American markets, with the European market alone valued at $8.37 billion in 2016.
The registration paves the way for Creso to sell the two products globally, following its application for a free sales certificate (for sales in Europe) and the impending application for a global import and export licence, with the company expecting to receive both these items by March.
However, Creso is still in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.
Given the group’s strong pipeline of new products across animal and human health market segments (as outlined below), there are likely to be multiple share price catalysts for Creso in 2017 and 2018. It should be noted here that the two animal products listed below have already received regulatory clearance and will be launched to market well ahead of Creso’s initial indications.
European registration to assist Creso in achieving its global expansion strategy
Management believes this latest development will assist Creso in meeting its goal of capturing a substantial share of the global companion animal market with its CBD nutraceuticals, and a leading market share of the hemp derived animal health market worldwide.
Key markets being targeted by Creso are Europe, the Middle East, the Gulf Region and Latin America as it looks to establish a leading market share of the hemp derived animal health market worldwide.
Given the group’s products have been proven to provide a strong alternative to existing therapies and targets medical conditions such as behavioural disorders, pain, arthritis and inflammation, there is the potential to gain an early mover competitive advantage in new markets.
Management explained that the number of treatment options available to veterinarians is limited as they are often human therapeutics that are poorly adapted to animals.
By comparison, Creso’s CBD animal health nutraceuticals are specifically formulated for various companion animal segments and contain very low THC, the psychoactive components of cannabis, importantly at levels below legal thresholds.
Multiple applications across the endocannabinoid system
The endocannabinoid system is a unique control regulatory system in all vertebrates and is involved in the regulation of numerous physiological processes that affect many important functions.
The primary function of the endocannabinoid system is to maintain a stable internal environment despite changes in the external environment, as diseases and ailments often emerge when there is a deficiency or dysfunction of the endocannabinoid system.
The aim of Creso’s CBD veterinary nutraceutical products is to supplement deficient and unbalanced naturally occurring endocannabinoids with cannabinoids from the hemp plant.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.